CVE-2017-6331

Public Exploit

Description

Prior to SEP 14 RU1 Symantec Endpoint Protection product can encounter an issue of Tamper-Protection Bypass, which is a type of attack that bypasses the real time protection for the application that is run on servers and clients.

7.1

CVSS

Severity: High

CVSS 3.1 •

CVSS 2.0 •

EPSS 2.20% Top 20%

Vendor Advisory symantec.com

Affected: Symantec Corporation Symantec Endpoint Protection

References

Link	Tags
https://www.exploit-db.com/exploits/43134/	issue tracking exploit vdb entry third party advisory
http://www.securityfocus.com/bid/101502	vdb entry third party advisory
http://www.securitytracker.com/id/1039775	vdb entry third party advisory
https://www.symantec.com/security_response/securityupdates/detail.jsp?fid=security_advisory&pvid=security_advisory&year=&suid=20171106_00	issue tracking vendor advisory

Frequently Asked Questions

What is the severity of CVE-2017-6331?: CVE-2017-6331 has been scored as a high severity vulnerability.
How to fix CVE-2017-6331?: To fix CVE-2017-6331, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2017-6331 being actively exploited in the wild?: It is possible that CVE-2017-6331 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~2% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2017-6331?: CVE-2017-6331 affects Symantec Corporation Symantec Endpoint Protection.

This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.